Incyte (INCY) said Thursday that the US Food and Drug Administration has approved Zynyz for the treatment of advanced squamous cell carcinoma of the anal canal in combination with chemotherapy and as a monotherapy.
Zynyz achieved a statistically significant improvement in progression-free survival and improvement in overall survival in SCAC patients, the company said.
Shares of Incyte were up almost 2% in recent trading.
Price: 62.36, Change: +1.20, Percent Change: +1.96
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.